Trial · NCT07884253
Energy Dose and Cardioversion Outcomes in AF
NCT07884253, Not applicable, Not yet recruiting, Second Affiliated Hospital, Zhejiang University, School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Energy Dose and Cardioversion Outcomes in AF. Trials, record NCT07884253. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07884253
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Energy Dose and Cardioversion Outcomes in AF
- NCT number
- NCT07884253
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 400 participants, estimated
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- Synchronized Electrical Cardioversion With Different Energy Strategies, Conventional Step-Up Energy Cardioversion
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | First-Shock Cardioversion Success Within 1 Minute | Within 1 minute after the first shock | Proportion of participants who return to sinus rhythm within 1 minute after the first synchronized electrical shock. |
| Primary | Overall Cardioversion Success Within 1 Minute | Within 1 minute after cardioversion | Proportion of participants who return to sinus rhythm within 1 minute after cardioversion, including any additional shocks given during the procedure. |
| Primary | First-Shock Cardioversion Success Maintained for at Least 30 Minutes | From the first shock through at least 30 minutes after restoration of sinus rhythm | Proportion of participants who return to sinus rhythm after the first shock and maintain sinus rhythm for at least 30 minutes. |
| Secondary | Change in Cardiac Injury Biomarkers | Within 24 hours before and 24 hours after cardioversion | Change from baseline in cardiac troponin and, if collected, creatine kinase and creatine kinase-MB. Baseline samples will be collected within 24 hours before cardioversion; follow-up samples will be collected 24 hours after cardioversion. Actual collection times will be recorded. |
| Secondary | Change in Renal Function Measures | Within 24 hours before and 24 hours after cardioversion | Change from baseline in serum creatinine and blood urea nitrogen, if measured as part of the study or routine clinical care. |
| Secondary | Cardioversion-Related Adverse Events | During cardioversion through 24 hours after cardioversion; serious adverse events through 30 days | Number and proportion of participants with arrhythmias, sinus node dysfunction, cardiac arrest, transient bradycardia, atrioventricular block, ventricular arrhythmia, thromboembolic events, or other serious adverse events. Events will be recorded during cardioversion and through 24 hours afterward; serious adverse events will be followed through 30 days. |
| Secondary | Skin Reaction at Electrode Sites | 2 hours after cardioversion | Skin findings at the anterior and posterior electrode sites, categorized as no redness, mild redness, or skin burn. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07884253
GET https://conductscience.org/api/trials/v1/NCT07884253/registered